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This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based 
on 3 hours of desk-based research each day. The summary is not intended to be a comprehensive 
summary of available evidence on COVID-19 but aims to make original documents easily 
accessible to decision makers which, if relevant to them, they should go to before making 
decisions. 
Clinical characteristics and management  
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
28.05.2020 Associations 
of 
hypertension 
with the 
severity and 
fatality of 
SARS-CoV-2 
infection: a 
meta-analysis 
Epidemiology & 
Infection | Meta-
analysis 
 Hypertensive patients were at 
a 3.48-fold higher risk of dying 
from COVID-19 (95% CI: 1.72-
7.08) 
 Pooled ORs of COVID-19 
fatality for hypertension vs 
non-hypertension was 6.43 
(95% CI: 3.40-12.17) and 2.66 
(95% CI: 1.27-5.57) in age 
<50y and >=50y patients 
respectively 
 Hypertension could 
significantly increase the risk 
of severity and fatality of 
SARS-CoVd-2 infection 
26.05.2020 Do the clinical 
management 
guidelines for 
Covid-19 in 
African 
countries 
Bull WHO | 
Review 
 This review identified and 
critically appraised the 
palliative care 
recommendations within 
COVID-19 case management 
guidelines in Africa 
2 
reflect the 
African quality 
palliative care 
standards? A 
rapid review 
 Governments and 
policymakers in Africa must 
prioritise palliative care within 
case management guidelines 
to ensure patients with 
COVID-19 have access 
 22.05.2020 Ventilation 
techniques 
and risk for 
transmission 
of coronavirus 
disease, 
including 
COVID-19: A 
living 
systematic 
review of 
multiple 
streams of 
evidence 
Annals of Internal 
Medicine | Review 
 A review of multiple streams of 
evidence regarding the 
benefits and harms of 
ventilation techniques for 
coronavirus infections, 
including that causing COVID-
19 
 A limitation was that direct 
studies in COVDI-19 are 
limited and poorly reported 
 Indirect and low-certainty 
evidence suggests that use of 
non-invasive ventilation, 
similar to invasive mechanical 
ventilation, probably reduces 
mortality but may increase the 
risk for transmission of 
COVID-19 to HCWs 
28.05.2020 Description of 
COVID-19 in 
HIV-infected 
individuals: a 
single-centre, 
prospective 
cohort 
The Lancet HIV | 
Article 
 This observational prospective 
study characterises individuals 
aged >=18y with COVID-19 among 
a cohort of HIV-infected adults in 
Madrid. Included as information 
about incidence, clinical 
characteristics and outcomes of 
HIV-infected individuals with 
SARS-CoV-2 infection is scarce 
 As of 30 April 2020, 51 COVID-19 
cases were diagnosed among a 
cohort of 2873 HIV-infected 
individuals 
 COVID-19 presented similar 
clinical, laboratory and radiological 
features in HIV-infected individuals 
compared with reports of the 
general population 
 Among HIV-infected individuals, 
lower CD4 cell counts affected 
disease severity and viral kinetics 
suggesting that those with low 
CD4 cell counts might have worse 
outcomes than individuals with 
restored immunity 
 HIV-infected individuals should 
receive the same treatment 
3 
approach applied to the general 
population 
28.05.2020 COVID-19 
mortality in 
patients with 
cancer on 
chemotherapy 
or other 
anticancer 
treatments: a 
prospective 
cohort study 
The Lancet | 
Article 
 This prospective observational 
study in the UK describes the 
clinical and demographic 
characterises and C19 outcomes 
in patients with cancer. Included as 
data from large multicentre studies 
to support the assumption that 
individuals with cancer are at 
increased risk of mortality from 
C19 are scarce 
 Authors did not identify evidence 
that cancer patients on cytotoxic 
chemotherapy or other anti-cancer 
treatments are at increased risk of 
mortality from C19, compared to 
those not on active treatment 
 Mortality from COVID-19 in cancer 
patients appears to be driven by 
age, sex and co-morbidities 
28.05.2020 Clinical 
impact of 
COVID-19 on 
patients with 
cancer 
(CCC19): a 
cohort study 
The Lancet | 
Article 
 This study characterises outcomes 
of a cohort of 928 patients aged 
>=18y with cancer and COVID-19 
from the USA, Canada and Spain 
from the COVID-19 and Cancer 
Consortium (CCC19) database 
diverse in terms of age distribution, 
race and ethnicity, cancer status, 
and whether on anticancer 
treatment. Included as data on 
patients with COVID-19 who have 
cancer are lacking 
 Among patients with cancer and 
COVID-19, 30-day all-cause 
mortality was high and associated 
with general risk factors and risk 
factors unique to patients with 
cancer 
25.05.20 Management 
of mild 
COVID-19: 
Policy 
implications of 
initial 
experience in 
India 
medRxiv| preprint 
(not peer 
reviewed) 
 Study aimed at describing clinical 
characteristics and outcomes of 
admitted patients with mild COVID-
19 illness in the initial phase of 
pandemic in India. 
 Conclusions - Patients with mild 
disease at presentation had a 
stable disease course and 
therefore such cases can be 
managed outside hospital setting. 
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Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
28.05.2020 
 
Asymptomatic 
transmission 
during the 
COVID-19 
pandemic 
and 
implications 
for public 
health 
strategies 
Clinical Infectious 
Diseases | 
Narrative review 
 This summary of evidence 
demonstrates the transmission 
potential of SARS-CoV-2 from 
asymptomatic and pre-
symptomatic individuals 
 Authors urge reassessment of 
public health strategies relying 
solely on ‘symptom’ onset for 
infection identification 
 Extensive universal 
testing  irrespective of symptoms 
should be considered with priority 
given to those with high frequency 
exposure to positive patients 
26.05.2020 Susceptibility 
to and 
transmission 
of COVID-19 
amongst 
children and 
adolescents 
compared 
with adults: a 
systematic 
review and 
meta-analysis 
medRxiv (non-
peer reviewed) / 
Systematic review 
 Children and adolescents under 
the age of 20 are much less likely 
than adults to become infected by 
the new coronavirus, finds a large 
systematic review of journal 
articles, preprints and reports. 
 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
 27.05.2020 
 
Small droplet 
aerosols in 
poorly 
ventilated 
spaces and 
SARS-CoV-2 
transmission 
The Lancet 
Respiratory 
Medicine | 
Comment 
 A study to better understand 
the spreading of respiratory 
droplets and possible 
preventive measures  
 Although only healthy 
volunteers were studied, data 
on droplet size distribution and 
persistence has implications 
5 
on requirements to use face 
masks to prevent virus 
transmission 
 Better ventilation of spaces 
substantially reduces the 
airborne time of respiratory 
droplets relevant in that 
typically poorly ventilated and 
populated spaces have 
reported sites of viral 
transmission despite 
preventive physical distancing 
25.05.20 
 
Coronavirus 
(COVID-19) 
infection in 
children at a 
specialist 
centre: 
outcome and 
implications 
of underlying 
high-risk 
comorbidities 
in a 
paediatric 
population 
medRxiv| preprint 
(not peer 
reviewed) 
 There is evolving evidence of 
significant differences in severity 
and outcomes of COVID-19 in 
children compared to adults. 
 In children presenting with pre-
existing COVID-19 vulnerable 
medical conditions at a specialist 
centre, there does not appear to be 
significantly increased risk of either 
contracting COVID-19 or severe 
complications, apart from those 
undergoing chemotherapy, who are 
over-represented. 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
 27.05.2020 Hydroxychloroquine 
or chloroquine for 
treatment or 
prophylaxis of 
COVID-19: A living 
systematic review 
Annals of 
Internal 
Medicine | 
Review 
 This review summaries 
evidence about the 
benefits and harms of 
hydroxychloroquine or 
chloroquine for the 
treatment or prophylaxis 
of COVID-19 
 No studies evaluated 
prophylaxis 
 Evidence was conflicting 
and insufficient regarding 
the effect of 
hydroxychloroquine on 
such outcomes as all-
6 
cause mortality, 
progression to severe 
diseases, clinical 
symptoms, and upper 
respiratory virologic 
clearance with antigen 
testing 
 Evidence on the benefits 
and harms of using 
hydroxychloroquine or 
chloroquine to treat 
COVID-19 is very weak 
and conflicting 
22.05.20 Remdesivir for the 
Treatment of Covid-
19 — Preliminary 
Report 
New England 
Journal of 
Medicine|Article 
 A trial of the drug remdesivir 
showed that it shortens the 
recovery of people 
hospitalized for COVID-19.  
 John Beigel at the National 
Institutes of Allergy and 
Infectious Diseases in 
Rockville, Maryland, and his 
colleagues studied more than 
1,000 people enrolled in a 
randomized, double- blind trial 
and found that those who took 
remdesivir had a median 
recovery time of 11 days, 
compared to 15 days for 
those who took a placebo. 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
28.05.2020 A vulnerability 
index for 
COVID-19: 
spatial 
analysis to 
inform 
equitable 
response in 
Kenya 
medRxiv 
|preprint (not 
peer reviewed) 
 3 vulnerability indices were used to 
identify areas and people who 
require greater support in the public 
health pandemic response to C19 in 
Kenya 
 The combined index of social and 
epidemiological vulnerabilities 
shows that on average 15% (7 
million) of Kenyans live in the most 
vulnerable sub-counties mainly 
located in the central and south-
eastern parts of Kenya 
 The heterogeneous nature of the 
vulnerability highlights the need to 
address social determinants of 
health disparities, strengthen the 
7 
health system and establish 
programmes to buffer against the 
impact of C19 
26.05.20 Digital Health 
Equity and 
COVID-19 – 
The Innovation 
Curve Cannot 
Reinforce the 
Social 
Gradient of 
Health 
Journal of 
Medical Internet 
Research | 
preprint 
 Poverty, lack of access to digital 
health, poor engagement with digital 
health for some communities, and 
barriers to digital health literacy are 
some factors that can contribute to 
poor health outcomes.  
 Here the Digital Health Equity 
Framework is presented, which can 
be used to consider health equity 
factors. Along with person-centered 
care, digital health equity should be 
incorporated into health provider 
training and should be championed 
at the individual, institutional, and 
social levels.  
21.05.20 Public 
knowledge, 
attitudes and 
practices 
towards 
COVID-19: A 
cross-sectional 
study in 
Malaysia 
PLOS ONE | 
Research article 
 Cross-sectional online survey of 
4,850 Malaysian residents was 
conducted between 27th March-3rd 
April 2020. 
 Respondents largely positive about 
way government was handling 
COVID-19. Most avoiding crowds 
and washing hands but fewer 
wearing masks. 
 The results highlight the importance 
of consistent messaging from health 
authorities and the government as 
well as the need for tailored health 
education programs to improve 
levels of knowledge, attitudes and 
practices. 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
30.05.2020 COVID-19 in Africa: no room 
for complacency 
The Lancet | Editorial   
30.05.2020 Fears of “highly catastrophic” 
COVID-19 spread in Yemen 
The Lancet | World Report Sharmila Devi 
29.05.2020 Covid-19 study on 
hydroxychloroquine use 
questioned by 120 
The Guardian | News Melissa Davey 
8 
researchers and medical 
professionals 
29.05.2020 COVID-19 research in Africa Science | Editorial Linda-Gail Bekker 
Valerie Mizrahi 
29.05.2020 Paying participants in 
COVID-19 trials 
The Journal of Infectious 
Diseases | Review 
Emily A. Largent 
Holly Fernandez 
Lynch 
28.05.2020 The starting line for COVID-
19 vaccine development 
The Lancet | Comment Nelson Lee 
Allison McGeer 
28.05.2020 COVID-19 in people with HIV The Lancet HIV | 
Comment 
Zhe Xu 
Chao Zhang 
Fu-Sheng Wang 
27.05.2020 A voice from the front line: 
reaching out of the box to 
engage private non-state 
healthcare actors in LMICs to 
combat COVID-19 
Health Policy and Planning 
| Blog 
Priya 
Balasubramaniam 
et al. 
May 2020 First measles, now COVID-
19 – are outbreaks finally 
moving the dial on vaccine 
hesitancy? 
LSHTM | Feature Jacqui Thornton 
June 2020 Obstacles to COVID-19 
control in east Africa 
The Lancet Infectious 
Diseases | Newsdesk 
Esther Nakkazi 
June 2020 A call for a global COVID-19 
neuro research coalition 
The Lancet Neurology | 
Correspondence 
Andrew Sylvia 
Winkler et al. 
28.05.2020 Covid-19: WHO halts 
hydroxychloroquine trial to 
review links with increased 
mortality risk  
BMJ | News   
9 
28.05.2020 COVID-19’s collateral 
damage could devastate low- 
and middle-income countries 
GAVI | Blog   
28.05.2020 How Mauritius’ unique 
political culture helped it beat 
COVID-19 
African Arguments | Blog Myriam Blin 
Jess Auerbach 
27.05.2020 Pandemic preparedness: 
developing vaccines and 
therapeutic antibodies for 
COVID-19 
Cell |Perspective Gregory D. 
Sempowski 
Kevin O. Saunders 
Priyamvada 
Acharya 
Kevin J. Wiehe 
Barton F. Haynes 
27.05.2020 The COVID-19 MS Coalition 
– accelerating diagnostics, 
prognostics, and treatment 
The Lancet | 
Correspondence 
Weston Struwe 
Edward Emmott 
Melanie Bailey 
Michal Sharon 
Andrea Sinz 
Fernando  J 
Corrales et al. 
27.05.2020 Ratio, rate, or risk? The Lancet Infectious 
Diseases | 
Correspondence 
Srinivas Mantha 
27.05.2020 Hydroxychloroquine: 
balancing the needs of 
LMICs during the COVID-19 
pandemic 
The Lancet Rheumatology 
| Correspondence 
Soumya Banerjee 
27.05.2020 Reducing transmission of 
SARS-CoV-2 
Science | Perspective Kimberly A. Prather 
Chia C. Wang 
Robert T. Schooley 
10 
27.05.2020 Tracking the gender impact 
of COVID-19 
CGD | Blog Mayra Buvinic 
Lorenz Noe 
Eric Swanson 
27.05.2020 Introducing the COVID-19 
multi-model comparison 
collaboration 
CGD | Blog Kalipso Chalkidou 
Marelize Gorgens 
Raymond 
Hutubessy 
Yot 
Teerawattananon 
David Wilson 
27.05.2020 Disease forecasting during 
the COVID-19 pandemic: 
have we learned from 
previous outbreaks 
CGD | Blog Hiral Anil Shah 
Kalipso Chalkidou 
26.05.2020 A tool to estimate the net 
health impact of COVID-19 
policies 
CGD | Blog Damian Walker 
Y-Ling Chi 
Florian Poli 
Kalipso Chalkidou 
26.05.2020 Adverse consequences of 
rushing a SARS-CoV-2 
vaccine: implications for 
public trust 
JAMA | Viewpoint Brit Trogen 
David Oshinsky 
Arthur Caplan 
22.05.2020 Cloth masks may prevent 
transmission of COVID-19: 
an evidence-based, risk-
based approach 
Annals of Internal 
Medicine | Ideas and 
Opinions 
Catherine M. Clase 
Edouard L. Fu 
Meera Joseph et al. 
26.05.20 Will the Pandemic Lead to 
Outbreaks of Other 
Maladies? 
New York Times | Opinion Anita Shet 
11 
26.05.20 Digital contact tracing poses 
ethical challenges 
John Hopkins University 
Q&A 
Jeffrey Kahn 
23.05.20 COVID-19: Exposing digital 
poverty in a pandemic 
International Journal of 
Surgery | Correspondence 
Matthew Seah 
22.05.20 India’s medical students and 
residents grapple with 
uncertain futures in the face 
of covid-19 
BMJ | Opinion Payel Biswas 
26.05.20 Physician Moms Group: the 
support network that’s 
needed more than ever 
during the covid-19 
pandemic 
BMJ | Feature Chris Stokel-Walker 
25.05.20 COVID-19 preparedness in 
Malawi: a national facility-
based critical care 
assessment 
Lancet Global Health | 
Correspondence 
Paul D Sonenthal et 
al. 
June 2020 A call for a global COVID-19 
Neuro Research Coalition 
Lancet Neurology | 
Correspondence 
 Andrea Sylvia 
Winkler et al. 
26.05.20 Scientific networks are 
helping African countries to 
access coronavirus lab 
supplies 
Nature | News  Linda Nordling 
26.05.20 Hunger could double in East 
Africa and the Horn in months 
as coronavirus spreads 
Scaling up Nutrition/ WFP   
27.05.20 Africa: Women and Children 
Will Pay For This Pandemic – 
Unless We Act 
All Africa | News By H.E. Kersti 
Kaljulaid, Rt Hon. 
Helen Clark, H.E. 
Jorge Alcocer 
Varela, and Hon. 
Graça Machel,  
22.05.20 Hydroxychloroquine 
prophylaxis for high-risk 
Lancet/  Correspondence Praveen Tilangi, 
Devashish Desai, 
12 
COVID-19 contacts in India: 
a prudent approach 
Adil Khan, Manish 
Soneja 
21.05.20 Detection of SARS-CoV-2 in 
human breastmilk 
Lancet/  Correspondence Rüdiger Groß 
Carina Conzelmann 
et al. 
  
1.06.20 Food insecurity will be the 
sting in the tail of COVID-19 
Lancet Global Health/ 
Editorial 
  
26.05.20 Invest in planetary health to 
build resilience, urges global 
health community 
UK Health Alliance on 
Climate Change’ 
  
25.05.20 Trump’s favoured drug 
shows no benefit — but 
another drug does 
Nature / News   
22.05.20 Translating Science on 
COVID-19 to Improve 
Clinical Care and Support the 
Public Health Response 
JAMA / Viewpoint Carlos del Rio, 
Preeti Malani, 
26.05.20 0.27% Rise in Infections 
Pushes Total of African 
COVID-19 Cases Over 
115,000 
All Africa / News   
26.05.20 Rwanda: COVID-19 - 
Researchers Discover New 
Method of Mass Testing 
All Africa / News   
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
26.05.20 Digital Contact 
Tracing for 
Pandemic 
Response: Ethics 
Johns 
Hopkins 
 Detailed guidelines to help manage the 
creation, implementation, and 
application of digital contact tracing.  
13 
and Governance 
Guidance 
University 
Press 
22.05.20 Covid-19 Rx: 
Treatment 
Simulations 
NEJM 
 The spectrum of Covid-19 
presentations ranges from mild self-
limited flu-like illness to life-threatening 
multi-organ failure. Prepare by 
engaging in these five treatment 
simulations from NEJM Group. 
26.05.20 WHO Manifesto 
for a healthy 
recovery from 
COVID-19 
WHO 1) Protect and preserve the source of 
human health: Nature 
2) Invest in essential services, from water 
and sanitation to clean energy in 
healthcare facilities. 
3) Ensure a quick healthy energy 
transition. 
4) Promote healthy, sustainable food 
systems. 
5) Build healthy, liveable cities. 
6) Stop using taxpayers money to fund 
pollution. 
  
 22.05.2020 Framework for 
decision-making: 
implementation 
of mass 
vaccination 
campaigns in the 
context of 
COVID-19 
WHO | 
Interim 
Guidance 
  Outlines a common framework for 
decision-making for the conduct of 
preventive and outbreak response 
campaigns 
 Considerations for implementing mass 
vaccination campaigns for prevention 
of increased risk of vaccine-
preventable diseases (VPD)/high 
impact diseases (HID) among 
susceptible populations 
 Details the risks and benefits of 
conducting vaccination campaigns to 
respond to VPD/HID outbreaks 
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Premise 
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Study 
    
  
Online learning & events  
Date Title/URL Online 
learning/event 
Duration Lead 
May 28 
09:30 am to 
11:00 am 
EDT 
Virtual Event - No 
backsliding: How can 
we re-orient food 
systems and health 
systems to protect 
nutrition and healthy 
diets in the context of 
COVID-19? 
Virtual event 1.5 hours IFPRI 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School 
of Nursing 
04.06.2020 
12pm ET 
CGD Conversations 
on COVID-19 and 
Development: John 
Nkengasong 
Event   CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
19 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
20 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based on 3 hours of 
desk-based research each day. The summary is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to decision 
makers which, if relevant to them, they should go to before making decisions. The HES are not intended to replace 
medical or professional advice and the researcher or the K4D consortium cannot be held responsible for any 
decisions made about COVID-19 on the basis of the HES alone. K4D services are provided by a consortium of 
leading organisations working in international development, led by the Institute of Development Studies (IDS), with 
Education Development Trust, Itad, University of Leeds Nuffield Centre for International Health and Development, 
Liverpool School of Tropical Medicine (LSTM), University of Birmingham International Development Department 
(IDD) and the University of Manchester Humanitarian and Conflict Response Institute (HCRI). 
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non-commercial purposes only. K4D cannot be held responsible for errors, omissions or any 
consequences arising from the use of information contained in this health evidence summary. 
Any views and opinions expressed do not necessarily reflect those of DFID, K4D or any other 
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